Cargando…

Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML

Complications of allogeneic hematopoietic stem cell transplantation (HSCT) have been attributed to immune cells transferred into the patient with the graft. However, a detailed immune cell composition of the graft is usually not evaluated. In the present study, we determined the level of variation i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Impola, Ulla, Larjo, Antti, Salmenniemi, Urpu, Putkonen, Mervi, Itälä-Remes, Maija, Partanen, Jukka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117118/ https://www.ncbi.nlm.nih.gov/pubmed/27917176 http://dx.doi.org/10.3389/fimmu.2016.00523

Ejemplares similares

Early CD8(+)-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT
por: Ranti, Juha, et al.
Publicado: (2018)

Computational Analysis of HLA-presentation of Non-synonymous Recipient Mismatches Indicates Effect on the Risk of Chronic Graft-vs.-Host Disease After Allogeneic HSCT
por: Ritari, Jarmo, et al.
Publicado: (2019)

Clinically relevant germline variants in allogeneic hematopoietic stem cell transplant recipients
por: Lahtinen, Atte K., et al.
Publicado: (2022)

Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD
por: Hyvärinen, Kati, et al.
Publicado: (2020)

Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation
por: Ritari, J., et al.
Publicado: (2018)

Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients
por: Impola, Ulla, et al.
Publicado: (2014)

Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety
por: Keto, Joni, et al.
Publicado: (2018)

Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia
por: Mäkelä, Eleonora, et al.
Publicado: (2019)

Hidden genomic MHC disparity between HLA-matched sibling pairs in hematopoietic stem cell transplantation
por: Koskela, Satu, et al.
Publicado: (2018)

Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma
por: Salmenniemi, Urpu, et al.
Publicado: (2012)

Exploring Transcriptomic Landscapes in Red Blood Cells, in Their Extracellular Vesicles and on a Single-Cell Level
por: Kerkelä, Erja, et al.
Publicado: (2022)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Battipaglia, Giorgia, et al.
Publicado: (2022)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
por: Yang, Guancui, et al.
Publicado: (2022)

Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients
por: Hobbs, Gabriela Soriano, et al.
Publicado: (2015)

Optimizing allogeneic grafts in hematopoietic stem cell transplantation
por: Xu, Zheng‐Li, et al.
Publicado: (2021)

A diffuse rash in a patient after allogeneic hematopoietic stem cell transplant for AML
por: Ferdjallah, Asmaa, et al.
Publicado: (2020)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

P1282: MOCRAVIMOD IMPROVES OVERALL SURVIVAL IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Medinger, Michael, et al.
Publicado: (2023)

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
por: Teich, Katrin, et al.
Publicado: (2023)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease
por: van Lier, Yannouck F., et al.
Publicado: (2023)

Impact of Pre-Transplant Measurable Residual Disease on Outcome of Allogeneic Hematopoietic Cell Transplantation in Adult Monosomal Karyotype AML
por: Morsink, Linde M., et al.
Publicado: (2020)

Pediatric donor cell leukemia after allogeneic hematopoietic stem cell transplantation in AML patient from related donor
por: Bobadilla-Morales, Lucina, et al.
Publicado: (2015)

Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation
por: Cao, Weijie, et al.
Publicado: (2022)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation
por: Partanen, Jukka, et al.
Publicado: (2020)

HLA allele-specific expression: Methods, disease associations, and relevance in hematopoietic stem cell transplantation
por: Johansson, Tiira, et al.
Publicado: (2022)

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
por: Kattner, Anna-Sophia, et al.
Publicado: (2020)

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities
por: Hassanein, Mona, et al.
Publicado: (2021)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
por: Braune, Jan, et al.
Publicado: (2022)

Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation
por: Simonetta, Federico, et al.
Publicado: (2017)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation
por: Chen, Juan, et al.
Publicado: (2020)

Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function
por: Arslan Davulcu, Eren, et al.
Publicado: (2023)

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
por: Jantunen, Esa, et al.
Publicado: (2023)

Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation
por: Du, Wei, et al.
Publicado: (2018)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

Allogeneic Hematopoietic Cell Transplantation and Cellular Therapy
por: Kim, Hee-Je, et al.
Publicado: (2021)

Accuracy of Programs for the Determination of Human Leukocyte Antigen Alleles from Next-Generation Sequencing Data
por: Larjo, Antti, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1siijq7jn8t8ob8pdrcoqfog46